Related Experiment Video
Updated: Jul 12, 2026
05:23
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Helicobacter pylori and non-malignant diseases
Theodore Rokkas1, Ilkay Simsek, Spiros Ladas
1Gastroenterology Department, Henry Dunant Hospital, Athens, Greece.
Helicobacter
|October 11, 2007
Summary
Helicobacter pylori eradication effectively treats peptic ulcers. For non-ulcer dyspepsia, H. pylori treatment offers a small benefit, potentially cost-effective, but more research is needed.
Area of Science:
- Gastroenterology
- Microbiology
- Clinical Medicine
Background:
- Focus on Helicobacter pylori (H. pylori) research has shifted towards gastric malignancy.
- The role of H. pylori in non-malignant conditions like peptic ulcer disease, GERD, and non-ulcer dyspepsia remains significant.
- Non-steroidal anti-inflammatory drug (NSAID) use interacts with H. pylori in gastric health.
Purpose of the Study:
- To review the clinical relevance of H. pylori in non-malignant gastrointestinal diseases.
- To assess the efficacy and cost-effectiveness of H. pylori eradication therapies for various conditions.
- To evaluate factors influencing H. pylori treatment outcomes and NSAID-induced gastric damage.
Main Methods:
- Literature review of H. pylori's role in peptic ulcer disease, GERD, and non-ulcer dyspepsia.
- Analysis of H. pylori eradication therapy effectiveness, including predictors like CagA status.
- Examination of the impact of H. pylori and NSAIDs on gastric health, including prostaglandin levels.
Main Results:
- H. pylori eradication therapy (1-2 weeks) is effective for H. pylori-positive peptic ulcers; positive CagA status predicts successful eradication.
- Antral prostaglandin-E2 levels are crucial for aspirin-induced gastric damage in H. pylori-negative individuals.
- H. pylori status does not influence GERD symptom relief in patients on proton-pump inhibitors.
- H. pylori testing strategies for dyspepsia may be more cost-effective than antisecretory therapy alone.
- H. pylori eradication provides a small, statistically significant benefit for H. pylori-positive non-ulcer dyspepsia, with potential cost-effectiveness.
Conclusions:
- H. pylori eradication is a key treatment for peptic ulcer disease.
- While H. pylori eradication offers a modest benefit for non-ulcer dyspepsia, its cost-effectiveness warrants consideration.
- Further research is necessary to fully elucidate the economic and clinical benefits of H. pylori management in non-malignant conditions.
Related Concept Videos
01:27Peptic Ulcer
Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
01:26Gastritis II: Pathophysiology
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
01:30Peptic Ulcer Disease I: Introduction
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:25Peptic Ulcer Disease I: Introduction
Peptic ulcer disease (PUD) involves breaks in the gastrointestinal tract's mucosal lining, primarily in the stomach and duodenum, with less frequent occurrences in the lower esophagus or near the pylorus.Ulcers can be acute or chronic. Acute ulcers are short-lived with minimal inflammation and heal quickly after the irritant is removed. Chronic ulcers persist, may recur, and often cause scarring due to ongoing tissue damage. Superficial erosions affect only the mucosal layer and are called...
01:24Peptic Ulcer Disease II: Pathophysiology
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
01:28Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.